Trials / Completed
CompletedNCT00088010
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer
Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 9,369 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Female
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study: * Effects of arzoxifene on bone fractures and bone mass. * Effects of arzoxifene on getting breast cancer. * Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. * Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health. * Effects of arzoxifene on the uterus. * The safety of arzoxifene and any side effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arzoxifene | 20mg, oral, tablet, once a day for 36 months |
| DRUG | Placebo | oral, tablet, once a day for 36 months |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2009-06-01
- Completion
- 2009-11-01
- First posted
- 2004-07-20
- Last updated
- 2010-06-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00088010. Inclusion in this directory is not an endorsement.